Provided by Tiger Trade Technology Pte. Ltd.

Lakewood-Amedex Biotherapeutics (Direct Listing)

0.9228
-0.0325-3.40%
Volume:113.37K
Turnover:104.69K
Market Cap:2.19M
PE:-0.30
High:0.9500
Open:0.9295
Low:0.9100
Close:0.9553
52wk High:98.20
52wk Low:0.9100
Shares:2.37M
Float Shares:1.39M
Volume Ratio:0.07
T/O Rate:8.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1006
EPS(LYR):-8.3987
ROE:-402.84%
ROA:-139.40%
PB:0.50
PE(LYR):-0.11

Loading ...

Lakewood-Amedex CEO Presents Nu-3 Preclinical Poster at IDWeek

Reuters
·
2 hours ago

Lakewood-Amedex Biotherapeutics Holds Annual Shareholder Meeting

Reuters
·
Sep 29

Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up 20% Today?

TIPRANKS
·
Sep 28

Lakewood-Amedex Biotherapeutics reports positive MIC data from Nu-3 study

TIPRANKS
·
Sep 28

Lakewood-Amedex Reports Positive MIC Data for Nu-3 Against Infected Diabetic Foot Ulcer Isolates

Reuters
·
Sep 28

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

THOMSON REUTERS
·
Sep 28

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

THOMSON REUTERS
·
Sep 24

Lakewood-Amedex Biotherapeutics Lists on NASDAQ Capital Market Under LABT Ticker

Reuters
·
Sep 21

Lakewood-Amedex Biotherapeutics - Prospectus Filed for Resale of up to 4,512,400 Shares of Common Stock by Certain Selling Stockholder - SEC Filing

THOMSON REUTERS
·
Sep 19

Lakewood-Amedex Biotherapeutics Announces Irb Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

THOMSON REUTERS
·
Sep 18

Lakewood-Amedex Biotherapeutics CEO Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 08

Lakewood-Amedex Q2 FY26 Net Loss Widens to $3.77 Million; R&D Expense More than Doubled to $503,020

Reuters
·
Aug 14

Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting

Reuters
·
Aug 11

Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting

Reuters
·
Jul 31

Lakewood-amedex Biotherapeutics Flags New Press Release Available on Nu-3 Resistance Data

Reuters
·
Jul 22

Lakewood-Amedex announces preclinical data from Phase 2a clinical trial

TIPRANKS
·
Jul 15

Lakewood-amedex Biotherapeutics Reports Release Available on Nu-3 Gel Preclinical Safety Data

Reuters
·
Jul 15

Lakewood-amedex Biotherapeutics - Finalizing Preparation for Phase 2a Trial in Infected Diabetic Foot Ulcers

THOMSON REUTERS
·
Jul 15

Lakewood-amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

THOMSON REUTERS
·
Jul 15

Lakewood-amedex Biotherapeutics - Nu-3 Well Tolerated at High Doses with Low Systemic Exposure in Preclinical Study

THOMSON REUTERS
·
Jul 15